Navigation Links
Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Date:8/23/2007

SOUTH SAN FRANCISCO, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will present updated results from its Phase 2 trial of picoplatin, including one-year survival data, during a poster discussion session at the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer in Seoul, Korea. Details follow:

Poster number: PD6-1-1

Title: A phase 2 study of picoplatin monotherapy for patients with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy

Presenter: David A. Karlin, M.D., senior vice president, clinical development and regulatory affairs, at Poniard

Date: Monday, September 3, at 4:00 p.m. local time

Location: Room 310 of the Coex Convention Center

About Picoplatin

Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the U.S. Food and Drug Administration (FDA) in November 2005 for picoplatin for the treatment of SCLC.

Poniard is currently evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Poniard is also evaluating intravenous pi
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Bank of ... , , , Date: , , , Wednesday, December 3, ... p.m. EST , , , , Location: , , , ... About BioScrip, Inc. BioScrip, Inc. is ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
(Date:11/26/2014)... and NEW YORK ... As the leading distributor of market intelligence, ... new research report by IQ4I Research and Consultancy focusing ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast to ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
... 19, 2011 Johnson & Johnson (NYSE: JNJ ... the investment community beginning at 9:00 a.m. (Eastern Time) on ... Brunswick, N.J. ending at approximately 3:00 p.m. Sheri ... Duato and Paul Stoffels, M.D. will host the meeting and ...
... data from multiple clinical trials supporting the safety and ... dual antiplatelet therapy (DAPT) is not advisable were featured ... and treat patients who are not suitable candidates for ... Presenters discussed current treatment alternatives to drug ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4
(Date:11/28/2014)... Agein.com, the Internet’s premier anti-aging web site focusing on anti-aging ... in the industry, is releasing its top diet and personal ... official start of winter is still three weeks away, but ... icy blast. After one of the worst winters in decades ... another brutal winter,” says Dr. Kevin J. McLaughlin, anti-aging and ...
(Date:11/28/2014)... 28, 2014 Junk-A-Car ( http://www.junkacar.com ), ... their service offerings to help drivers, especially those in ... Washington, D.C. metropolitan areas deal with the especially harsh ... large part of the country. , With the high ... hundreds of totaled, crashed and junk cars, ...
(Date:11/28/2014)... 2014 Dr. Andrew Campbell, one of ... the expansion of Quintessa Aesthetic Center into a third ... at W307 N1497 Golf Road in Suite 200 and ... Campbell, the new Delafield location will offer a variety ... including: Botox, filler injectables , micro laser peels, ...
(Date:11/28/2014)... Minneapolis, Minnesota (PRWEB) November 28, 2014 ... one of the few insurance marketing organizations in ... the income and asset protection marketplace. Secura Consultants ... in partnership with Principal Financial Group, a leading ... with multiple ownership interests. With the ownership interest ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3
... the United States suggests that the odds of firefighters dying ... fire, //are 10 to 100 times higher than during non-emergency ... ,Stefanos Kales of Harvard Medical School and colleagues say ... in smoke, and lack of physical fitness appeared responsible for ...
... a flight attendant. She started exercising two years back and ... keen that she be agile and strong. ,She ... Her exercise regimen includes balancing on one leg, working with ... fall and break her bones. ,Health experts ...
... used ingredient in the Indian curry powder, could be ... ,ASC-J9, a synthetic chemical compound, derived from ... considerable promise against prostate cancer, acne, and enlarged prostate, ... researchers at the University of Rochester Medical Center ...
... Larry E. Miller and team from Virginia Polytechnic Institute and ... men after one year of coronary artery bypass grafting (CABG). ... than one coronary artery which pass through the heart to ... Twenty six men between the ages of 50 and 79 ...
... only recorded case, turns a mild mannered 70-year-old man into a ... his wife have ‘nightmares’ during the day, of the night to ... after, a different person. He shouts, uses the foulest language, sleepwalks, ... Rogers has broken his nose thrice, ...
... people are turning to the Internet to find information, important ... sheer avalanche of facts// now available online. Key science sites ... results. ,New research funded by the Economic and ... Web to make their information available must now pay attention ...
Cached Medicine News:Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2Health News:Key Science Web Sites Buried in Information Avalanche 2
...
Stab incision blades color coded for simple and accurate identification...
Atkinson needles have a single bevel with a 22 angle point. Injecting anesthetic agents into the muscle cone. 0.60mm x 38.0mm (23 G x 1 1/2 in)...
Designed to lift corneal cap/flap during corneal lamellar surgery...
Medicine Products: